Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Lars H. Jensen, Rikke Fredslund Andersen, Lene Byriel, Eva Fernebro, Anders Jakobsen, Jan Lindebjerg, Lise Nottelmann, John Ploen & Torben F. Hansen. (2020) Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers. Acta Oncologica 59:3, pages 298-301.
Read now
Read now
Finn Ole Larsen, Dan Taksony Solyom Hoegdall, Estrid Hoegdall & Dorte Nielsen. (2016) Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma. Acta Oncologica 55:3, pages 382-385.
Read now
Read now
Finn Ole Larsen, Anne Haahr Mellergaard, Dan Taksony Solyom Hoegdall & Lars Henrik Jensen. (2014) Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma. Acta Oncologica 53:10, pages 1448-1450.
Read now
Read now
Articles from other publishers (13)
Nadia Emad Lotfi Amin, Torben Frøstrup Hansen, Eva Fernebro, John Ploen, Jakob Eberhard, Jan Lindebjerg & Lars Henrik Jensen. (2021)
Randomized
Phase II
trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without
KRAS
exon 2 mutations
. International Journal of Cancer 149:1, pages 119-126.
Crossref
Crossref
Mairéad Geraldine McNamara, Andre Lopes, Harpreet Wasan, David Malka, David Goldstein, Jenny Shannon, Takuji Okusaka, Jennifer J. Knox, Anna Dorothea Wagner, Thierry André, David Cunningham, Markus Moehler, Lars Henrik Jensen, Dieter Koeberle, Tanios Bekaii-Saab, John Bridgewater & Juan W. Valle. (2020) Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. Journal of Hepatology 73:5, pages 1109-1117.
Crossref
Crossref
Alice Markussen, Lars Henrik Jensen, Laura Vittrup Diness & Finn Ole Larsen. (2020) Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial. Cancers 12:7, pages 1975.
Crossref
Crossref
Pablo Sala Elarre, Esther Oyaga-Iriarte, Kenneth H. Yu, Vicky Baudin, Leire Arbea Moreno, Omar Carranza, Ana Chopitea Ortega, Mariano Ponz-Sarvise, Luis D. Mejías Sosa, Fernando Rotellar Sastre, Blanca Larrea Leoz, Yohana Iragorri Barberena, Jose C. Subtil Iñigo, Alberto Benito Boíllos, Fernando Pardo & Javier Rodríguez Rodríguez. (2019) Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse. Cancers 11:5, pages 606.
Crossref
Crossref
Weijing Sun, Anuj Patel, Daniel Normolle, Krishna Patel, James Ohr, James J. Lee, Nathan Bahary, Edward Chu, Natalie Streeter & Summer Drummond. (2018) A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer 125:6, pages 902-909.
Crossref
Crossref
Mairéad Geraldine McNamara, John Bridgewater, Andre Lopes, Harpreet Wasan, David Malka, Lars Henrik Jensen, Takuji Okusaka, Jennifer J. Knox, Dorothea Wagner, David Cunningham, Jenny Shannon, David Goldstein, Markus Moehler, Tanios Bekaii-Saab & Juan W. Valle. (2017) Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. BMC Cancer 17:1.
Crossref
Crossref
Da-long Yin, Ying-jian Liang, Tong-sen Zheng, Rui-peng Song, Jia-bei Wang, Bo-shi Sun, Shang-ha Pan, Lian-dong Qu, Jia-ren Liu, Hong-chi Jiang & Lian-xin Liu. (2016) EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma. Scientific Reports 6:1.
Crossref
Crossref
Toshikazu Moriwaki, Hiroyasu Ishida, Masahiro Araki, Shinji Endo, Shigemasa Yoshida, Mariko Kobayashi, Yukako Hamano, Akinori Sugaya, Masahiro Shimoyamada, Naoyuki Hasegawa, Mamiko Imanishi, Yuka Ito, Daiki Sato & Ichinosuke Hyodo. (2015) Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer. Journal of Hepato-Biliary-Pancreatic Sciences 22:9, pages 669-674.
Crossref
Crossref
Mie Grunnet, Ib J. Christensen, Ulrik Lassen, Lars H. Jensen, Magnus Lydolph, Jennifer J. Knox, Mairead G. McNamara, Mark Jitlal, Harpreet Wasan, John Bridgewater, Juan W. Valle & Morten Mau-Sorensen. (2015) Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. European Journal of Cancer 51:11, pages 1381-1388.
Crossref
Crossref
M. Grunnet, I.J. Christensen, U. Lassen, L.H. Jensen, M. Lydolph, I.K. Lund, T. Thurison, G. Høyer-Hansen & M. Mau-Sørensen. (2014) Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients. Clinical Biochemistry 47:7-8, pages 599-604.
Crossref
Crossref
Rocio I. R. Macias. (2014) Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. ISRN Hepatology 2014, pages 1-13.
Crossref
Crossref
G. Rubovszky, I. Láng, E. Ganofszky, Z. Horváth, É. Juhos, T. Nagy, E. Szabó, Z. Szentirmay, B. Budai & E. Hitre. (2013) Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study. European Journal of Cancer 49:18, pages 3806-3812.
Crossref
Crossref
L.H. Jensen, J. Lindebjerg, J. Ploen, T.F. Hansen & A. Jakobsen. (2012) Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Annals of Oncology 23:9, pages 2341-2346.
Crossref
Crossref